Pharma China Annual Forum 2019

April 9th, 2019

Each year there are more uncertainties surrounding China healthcare and 2019 is no exception. Despite some positive developments on the front of Chinese drug registration regime, which has substantially accelerated its evaluation and approval of innovative new drugs, the pharmaceutical industry in China is faced with another overhaul of its business model, fast changing marketplace and repeated assaults of its bottom-lines following establishment of the State Medical Insurance Administration (SMIA), introduction of national level volume-linked centralized drug purchase tender trial, and advancement of the generic quality and clinical equivalence (GQCE) program which aims to replace off-patent MNC originator drugs with local GQCE products.

 

 

While the Chinese pharmaceutical manufacturing industry saw its operating revenues grow by 13.5% (above average of 9.4% for all industries in China) to CNY 20,181 billion in the first ten months of 2018, the industry’s profits rose only 10.4% (below average of 13.6% for all Chinese industries) to CNY 255 billion in the period, according to official data from the National Statistics Bureau.

Structural issues with the Chinese healthcare system continued to haunt the pharmaceutical industry in 2018. Notwithstanding the touted pharma industry ambitions of the Chinese government, slogans are nothing but pies in the sky when it comes to paying for better medicines. The healthcare reform has long been hijacked by cost containment and gone astray from the pledged path of improving efficiency and fixing structural flaws. The crashing course of reform is deeply rooted in the growing contradictions between wishful goals and healthcare financial reality, as well as among different government policies and their pursuits.

Organizer: Pharma China
Sponsor(s): RDPAC, Kantar Health, Others TBA
Date: 9 AM to 5:15 PM, April 9, 2019
Venue: Le Royal Shanghai, Shanghai, China

Fees
: CNY 6,400 ($930) for Pharma China subscribers and employees of RDPAC member companies. CNY 6,800 ($980) for others (credit card acceptable at 3% charge for US$ payments)

Event Highlights

  • Contemporary trends & issues in Chinese Pharma in 2018 and early 2019
  • Business, healthcare reform and regulatory outlook for 2019 and beyond
  • Changing dynamics in Chinese pharma/healthcare landscape
  • Evolving new business model and pharma sales & marketing strategies
  • Trends and strategies for market access, drug R&D, partnership and licensing
  • Interactive discussion and brainstorming with our panel of top experts

With tax and other revenues drying up and under increasing threat of BMI system deficit amid a looming Chinese economic downturn, local governments are pressured by both the central government and the public to do more for healthcare with less financial resources. As local governments assaulted the pharma industry above the table with wave after wave of cost containment measures, public hospitals also squeezed drug companies under the table for funds through a variety of schemes. Shortage of low cost but clinically essential medicines has become widespread, forcing the central government to step in and often intervene administratively.

Incidentally, 2018 turned out to be a triumphant time for MNCs. A number of pharma MNCs witnessed unexpected high growth last year ahead of the flood of local GQCE products. Despite naive overjoys of some executives, such inadvertent victories are not expected to last in 2019.

The Chinese economy and the reform of its healthcare system are once again in deep water of what’s become of a « lost river ». Pharma companies, local or foreign, must make dynamic changes to remain competitive and survive with the turbulent market.

The Pharma China Annual Forum 2019 is an English language annual pharma industry event oriented for foreign drug companies in China. It is sponsored by RDPAC, Kantar Health and WiCON International Group LLC, the publisher of WiCON|Pharma China. The event’s emphasis is on healthcare policies, drug regulations, market access and strategic issues as well as potential impacts of latest and upcoming policy changes on the Chinese pharma industry. In addition, contemporary trends of M&As, R&D and licensing, IPR, business hotspots and e-commerce, as well as future market outlook will be explored and discussed. 14 leading experts will share their knowledge, insights and expertise.